Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
KSD-201 in Renal Cell Carcinoma: NCT06708936 Clinical Landscape Report 2026
15 October 2026
NCT06708936 clinical landscape for Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Mupirocin in Soft Tissue Sarcoma: NCT06712433 Clinical Landscape Report 2026
15 October 2026
NCT06712433 clinical landscape for Soft Tissue Sarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Adrixetinib in Recurrent Follicular Lymphoma: NCT06712810 Clinical Landscape Report 2026
15 October 2026
NCT06712810 clinical landscape for Recurrent Follicular Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Olaparib in Endometrial Carcinoma: NCT06712472 Clinical Landscape Report 2026
15 October 2026
NCT06712472 clinical landscape for Endometrial Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Roginolisib in Uveal Melanoma: NCT06717126 Clinical Landscape Report 2026
15 October 2026
NCT06717126 clinical landscape for Uveal Melanoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Lobaplatin in Osteosarcoma: NCT06714383 Clinical Landscape Report 2026
15 October 2026
NCT06714383 clinical landscape for Osteosarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Ipilimumab in Melanoma: NCT06712927 Clinical Landscape Report 2026
15 October 2026
NCT06712927 clinical landscape for Melanoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
BL-M17D1 in HER2 Mutation Lung Cancer: NCT06714617 Clinical Landscape Report 2026
15 October 2026
NCT06714617 clinical landscape for HER2 Mutation Lung Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Cabozantinib (s)-Malate in Metastatic Renal Cell Carcinoma: NCT06716853 Clinical Landscape Report 2026
15 October 2026
NCT06716853 clinical landscape for Metastatic Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Metabolically Armed CD19 CAR-T cells(Leman Biotech ) in B-Cell Lymphoma: NCT06716164 Clinical Landscape Report 2026
15 October 2026
NCT06716164 clinical landscape for B-Cell Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Prednisolone sodium metazoate in Diffuse Large B-Cell Lymphoma: NCT06717347 Clinical Landscape Report 2026
15 October 2026
NCT06717347 clinical landscape for Diffuse Large B-Cell Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Temozolomide in Solid tumor: NCT06721689 Clinical Landscape Report 2026
15 October 2026
NCT06721689 clinical landscape for Solid tumor: endpoints, sponsor, phase, geography, readouts, asset context and development white space.